Adam Maya, Klapow Maxwell, Greuel Merlin, Seeff Misha, Rohr Julia K, Gordon Andrew, Amsalem Doron, Bärnighausen Till
Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.
Heidelberg Institute of Global Health, University Hospital Heidelberg, Heidelberg, Germany.
JMIR Res Protoc. 2025 May 5;14:e73382. doi: 10.2196/73382.
Stigma toward people with addiction is a well-documented phenomenon that dramatically impacts help-seeking, treatment, and recovery. Interventions aimed at reducing stigma toward those with addiction must overcome the frequent mischaracterization of addiction as a failure of judgment rather than a chronic, treatable illness. Previous research has demonstrated that social contact with people recovering from addiction can promote empathy and reduce stigma, but social contact is difficult to scale. Short, animated storytelling (SAS) is a novel health communication approach that scales easily because it can leapfrog barriers associated with language, culture, literacy, and education levels.
This study will investigate the effect of a cross-culturally accessible SAS video intervention aimed at reducing stigma and increasing empathy toward people with addiction. We also seek to gain insight into the mechanisms of action of this SAS intervention by measuring the contribution of sound design to their effect.
We will conduct a randomized controlled trial with 13,500 adult participants from the United States, the United Kingdom, and South Africa, recruited online via Prolific Academic and randomized into 3 arms, per country. The 2 intervention arms will receive a wordless, social contact-based SAS video, one arm with a soundtrack and one without. The third arm will receive an educational video about addiction. Validated questionnaires will be used to assess our primary outcome, addiction stigma, and secondary outcomes, optimism, warmth toward the subject, and hopefulness, at baseline, immediately post exposure, and 2 weeks later. Ethics clearance was obtained on August 15, 2024, from the Stanford University institutional review board (protocol 76457).
This trial was funded in January 2025 by the Heidelberg Institute of Global Health, the Faculty of Medicine at Heidelberg University, in Germany. As of March 2025, no data have been collected. The estimated start date for this trial is May 15, 2025. We expect to complete data collection by July 1, 2025, and expect results to be published in the spring of 2026.
Here, we present the protocol for an online, multicountry, randomized controlled trial. This trial is designed to measure the effect of an innovative approach to global health communication (wordless, short, and animated storytelling) on addiction stigma in 3 global regions. These findings will inform the design of future scalable, digital health storytelling interventions for global audiences while exploring the capacity of SAS to shift public health attitudes and perceptions. Furthermore, if effective, the intervention described here could be disseminated broadly via social media and other online platforms.
ClinicalTrials.gov NCT06705205; https://clinicaltrials.gov/study/NCT06705205.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/73382.
对成瘾者的污名化是一个有充分记录的现象,对寻求帮助、治疗和康复产生了巨大影响。旨在减少对成瘾者污名化的干预措施必须克服成瘾常被错误地描述为判断力不足而非慢性可治疗疾病这一问题。先前的研究表明,与成瘾康复者的社交接触可以促进同理心并减少污名化,但社交接触难以规模化。简短的动画故事讲述(SAS)是一种新颖的健康传播方法,因其可以跨越与语言、文化、读写能力和教育水平相关的障碍而易于规模化。
本研究将调查一种跨文化通用的SAS视频干预措施对减少对成瘾者的污名化及增强同理心的效果。我们还试图通过测量声音设计对其效果的贡献来深入了解这种SAS干预措施的作用机制。
我们将对来自美国、英国和南非的13500名成年参与者进行一项随机对照试验,通过Prolific Academic在线招募,并按国家随机分为3组。两个干预组将观看一个基于社交接触的无声SAS视频,一组有配乐,一组没有。第三组将观看一个关于成瘾的教育视频。在基线、接触后立即以及2周后,将使用经过验证的问卷来评估我们的主要结果——成瘾污名,以及次要结果——乐观情绪、对该主题的温暖感和希望感。2024年8月15日获得了斯坦福大学机构审查委员会的伦理批准(方案编号76457)。
该试验于2025年1月由德国海德堡大学医学院的海德堡全球健康研究所资助。截至2025年3月,尚未收集到任何数据。该试验的预计开始日期为2025年5月15日。我们预计在2025年7月1日前完成数据收集,并预计结果将于2026年春季发表。
在此,我们展示了一项在线、多国、随机对照试验的方案。该试验旨在衡量一种创新的全球健康传播方法(无声、简短且动画形式的故事讲述)对全球三个地区成瘾污名的影响。这些发现将为未来针对全球受众的可扩展数字健康故事讲述干预措施的设计提供信息,同时探索SAS改变公众健康态度和认知的能力。此外,如果有效,此处描述的干预措施可以通过社交媒体和其他在线平台广泛传播。
ClinicalTrials.gov NCT06705205;https://clinicaltrials.gov/study/NCT06705205。
国际注册报告识别码(IRRID):PRR1-10.2196/73382。